


PATENT
Docket No. 500862001602
Client Ref. REDC-16

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL9684177⁰⁴US

Date of Deposit: November 25, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.



Victoria Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Dominique BRIDON et al.

Serial No.: Not Yet Assigned

Filing Date: Concurrently Herewith

For: LONG LASTING SYNTHETIC
GLUCAGON LIKE PEPTIDE (GLP-1)

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of references #19 and #20 are submitted herewith. Copies of the documents #1-18 and 21-42 were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/288,340, filed November 4, 2002, or are not required to be submitted pursuant to USPTO waiver of 37 CFR 1.98(a)(2)(i) and accordingly, copies are not

included herewith This protocol conforms with 37 CFR § 1.98(d) and M.P.E.P. 609(A)(2).

The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☒ With the application; accordingly, no fee or separate requirements are required.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document or the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **500862001602**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 25, 2003

Respectfully submitted,

By: 
Cameron A. King
Registration No. 41,897

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-7000
Facsimile: (415) 268-7522

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 500862001602	Application Number Not Yet Assigned
	Applicant Dominique BRIDON et al.	
	Filing Date Concurrently Herewith	Group Art Unit Not Yet Assigned
	Mailing Date November 25, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	6/1992	5,118,666	Habener			
	2.	6/1992	5,120,712	Habener			
	3.	2/1996	5,493,007	Burnier et al.			
	4.	8/1996	5,545,618	Buckley et al.			
	5.	11/1996	5,574,008	Johnson et al.			
	6.	3/1997	5,612,034	Pouletty et al.			
	7.	3/1997	5,614,487	Battersby et al.			
	8.	3/1997	5,614,492	Habener			
	9.	9/1999	5,958,909	Habener			
	10.	11/1999	5,981,488	Hoffman			
	11.	8/2000	6,107,489	Krantz et al.			
	12.	10/2000	6,133,235	Galloway et al.			
	13.	2/2001	6,191,102 B1	DiMarchi et al.			
	14.	12/2001	6,329,336	Bridon, et al.			
	15.	2/2003	6,514,500	Bridon et al.			
	16.	7/2003	6,593,295	Bridon et al.			
	17.	6/2000	09/876,388	Bridon, et al.			
	18.	9/2000	09/657,332	Bridon, et al.			
	19.	9/2000	09/657,276	Bridon et al.			
	20.	11/2002	2003/0108567	Bridon et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	21.	8/1991	WO 91/11457	PCT			
	22.	12/1993	WO 93/25579	PCT			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 500862001602	Application Number Not Yet Assigned
	Applicant Dominique BRIDON et al.	
	Filing Date Concurrently Herewith	Group Art Unit Not Yet Assigned
	Mailing Date November 25, 2003	

	23.	4/1995	WO 95/10302	PCT				
	24.	3/1998	WO 98/08531	PCT				
	25.	3/1998	WO 98/08871	PCT				
	26.	3/1998	WO 98/08873	PCT				
	27.	10/1998	WO 98/43658	PCT				
	28.	5/1999	WO 99/24074	PCT				
	29.	5/1999	WO 99/24075	PCT				
	30.	6/1999	WO 99/29336	PCT				
	31.	9/1999	WO 99/48536	PCT				
	32.	12/2000	WO 00/76550	PCT				
	33.	12/2000	WO 00/76551	PCT				
	34.	6/1994	0602290	EPO				
	35.	1/2000	0969016	EPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	36.	Ishikawa, E. et al. (October 7, 1978) "Enzyme-Labeling with Maleimides and Its Application to the Immunoassay of Peptide Hormones" Enzyme Labelled Immunoassay of Hormones and Drugs, Walter deGruyter & Co., Berlin, New York: 43-57.
	37.	Proc. Natl. Acad. Sci., 1983, 80, 5485-5489.
	38.	Nature, 1983, 302, 716-718.
	39.	Endocrinol., 1984, 115, 2176-2181.
	40.	Marburg et al. (1996) "Introduction of the Maleimide Function onto Resin-Bound Peptides: A simple, High yield Process Useful for Discriminating among several lysines," Bioconjugate Chemistry, Vol. 7, pp/ 612-616.
	41.	Anti-Cancer Drugs, 1997, 8, 677-685.
	42.	Siegel et al. (1999) "Biological Activity of GLP-1 analogues with N-terminal modifications," Regulatory Peptides, Vol. 79, issue 23, pp. 93-102.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.